{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T15:10:52Z","timestamp":1742397052048,"version":"3.33.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Toxic epidermal necrolysis (TEN), a severe cutaneous hypersensitivity reaction induced particularly by drugs, is diagnosed when there is a fever of\u2009\u2265\u200938\u00a0\u00b0C, mucocutaneous symptoms, a rash with multiple erythema, and skin peeling of\u2009\u2265\u200930% of the body surface area. The mortality rate of TEN is high, and thrombocytopenia during treatment can lead to severe outcomes. Intravenous immunoglobulin (IVIg) is used when steroids are ineffective in TEN and may improve mortality; however, thrombocytopenia is a rare adverse event associated with IVIg use. We report the case of thrombocytopenia during IVIg therapy for TEN. We also reviewed previous reports to learn more about the clinical course and mechanism of IVIg-induced thrombocytopenia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation<\/jats:title>\n            <jats:p>An 83-year-old man with end-stage renal failure on hemodialysis was diagnosed with TEN. After an inadequate response to pulse methylprednisolone therapy, IVIg (400\u00a0mg\/kg\/day) was administered for 5\u00a0days. He developed thrombocytopenia after IVIg administration, leading to the diagnosis of thrombocytopenia due to IVIg after excluding other diseases. The platelet count began to increase approximately 10\u00a0days after IVIg administration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>When IVIg is administered for TEN, the risk of thrombocytopenia should be recognized and the platelet count should be carefully monitored.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40780-024-00405-2","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T23:02:11Z","timestamp":1738018931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Toxic epidermal necrolysis with thrombocytopenia induced by intravenous immunoglobulin: a case report and mini review"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-4443","authenticated-orcid":false,"given":"Yoshihiro","family":"Nishita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Taga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sawako","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiaki","family":"Taga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Togen","family":"Masauji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"405_CR1","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","volume":"136","author":"DY Hsu","year":"2016","unstructured":"Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol. 2016;136:1387\u201397.","journal-title":"J Invest Dermatol"},{"key":"405_CR2","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/09546634.2019.1568380","volume":"30","author":"AK Tran","year":"2019","unstructured":"Tran AK, Sidhu S. Stevens Johnson syndrome and toxic epidermal necrolysis - an Australian analysis of treatment outcomes and mortality. J Dermatolog Treat. 2019;30:718\u201323.","journal-title":"J Dermatolog Treat"},{"key":"405_CR3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/pds.3937","volume":"25","author":"J Diphoorn","year":"2016","unstructured":"Diphoorn J, Cazzaniga S, Gamba C, Schroeder J, Citterio A, Rivolta AL, et al. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry. Pharmacoepidemiol Drug Saf. 2016;25:196\u2013203.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"405_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jaad.2021.02.046","volume":"86","author":"S Patel","year":"2022","unstructured":"Patel S, Cadwell JB, Lambert WC. Effect of older age on complications and mortality in inpatients with Stevens-Johnson syndrome or toxic epidermal necrolysis. J Am Acad Dermatol. 2022;86:665\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"405_CR5","first-page":"1633","volume":"129","author":"C Usuda","year":"2019","unstructured":"Usuda C, Nagai A, Kobayashi T, Sugiura K. A case of bullous pemphigoid who received repetitive treatments with intravenous immunogloblin resulted in thrombocytopenia. Jpn J Dermatol. 2019;129:1633\u20138. Japanese.","journal-title":"Jpn J Dermatol."},{"key":"405_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12959-017-0142-4","volume":"15","author":"H Wada","year":"2017","unstructured":"Wada H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Kawasugi K, et al. The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. DIC subcommittee of the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2017;15:17.","journal-title":"Thromb J."},{"key":"405_CR7","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1111\/j.1538-7836.2007.02617.x","volume":"5","author":"A Greinacher","year":"2007","unstructured":"Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4\/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost. 2007;5:1666\u201373.","journal-title":"J Thromb Haemost"},{"key":"405_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1160\/TH16-06-0482","volume":"117","author":"T Maeda","year":"2017","unstructured":"Maeda T, Nakagawa K, Murata K, Kanaumi Y, Seguchi S, Kawamura S, et al. Identifying patients at high risk of heparin-induced thrombocytopenia-associated thrombosis with a platelet activation assay using flow cytometry. Thromb Haemost. 2017;117:127\u201338.","journal-title":"Thromb Haemost"},{"key":"405_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"39","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;39:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"405_CR10","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1097\/CCM.0b013e3181de0b88","volume":"38","author":"JL Priziola","year":"2010","unstructured":"Priziola JL, Smythe MA, Dager WE. Drug-induced thrombocytopenia in critically ill patients. Crit Care Med. 2010;38:S145\u201354.","journal-title":"Crit Care Med"},{"key":"405_CR11","first-page":"159","volume":"42","author":"N Kashiwagi","year":"2022","unstructured":"Kashiwagi N, Murakoshi M, Ogasawara K, Yamazaki Y, Kanamori T, Utagawa T, et al. A case of steroid-resistant nephrotic syndrome with thrombocytopenia and anemia after immunoglobulin infusion. J Jpn Soc Pediatr Ren Fail. 2022;42:159\u201362. Japanese.","journal-title":"J Jpn Soc Pediatr Ren Fail."},{"key":"405_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s002280050272","volume":"52","author":"U Pedersen-Bjergaard","year":"1997","unstructured":"Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol. 1997;52:183\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"405_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/trf.14419","volume":"58","author":"A Gurevich-Shapiro","year":"2018","unstructured":"Gurevich-Shapiro A, Bonstein L, Spectre G, Atweh N, Gruenewal T, Shapiro M, et al. Intravenous immunoglobulin\u2013induced acute thrombocytopenia. Transfusion. 2018;58:493\u20137.","journal-title":"Transfusion"},{"key":"405_CR14","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1111\/trf.13105","volume":"55","author":"R Berg","year":"2015","unstructured":"Berg R, Jacob D, Fuellenhals E. Hemolytic events after the administration of lyophilized versus liquid immune globulin: an analysis of a single manufacturer\u2019s safety database. Transfusion. 2015;55:1847\u201354.","journal-title":"Transfusion"},{"key":"405_CR15","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1111\/trf.13097","volume":"55","author":"J Pendergrast","year":"2015","unstructured":"Pendergrast J, Willie-Ramharack K, Sampson L, Laroche V, Branch DR. The role of inflammation in intravenous immune globulin\u2013mediated hemolysis. Transfusion. 2015;55:S65-73.","journal-title":"Transfusion"},{"key":"405_CR16","first-page":"318","volume":"40","author":"S Shimano","year":"1999","unstructured":"Shimano S, Murayama K, Yokohama A, Murata N, Tsuchiya J. Marked thrombocytopenia after high-dose intravenous gamma globulin in a pregnant woman with idiopathic thrombocytopenic purpura. Rinsho Ketsueki. 1999;40:318\u201323. Japanese.","journal-title":"Rinsho Ketsueki."}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00405-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-024-00405-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-024-00405-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T23:02:14Z","timestamp":1738018934000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-024-00405-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["405"],"URL":"https:\/\/doi.org\/10.1186\/s40780-024-00405-2","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Verbal informed consent was obtained from the patient to publish this report in accordance with the journal\u2019s patient consent policy and was documented in the medical record.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}